Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2021

View Archived Issues

THAP1 gene variation associated with neurodevelopmental disorders and impaired myelination

CD300a blockade ameliorates neuronal deficit after ischemic stroke

Adding MGMT-modified gamma-delta T cells to temozolomide in models of high-grade gliomas

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents HBV HBsAg secretion inhibitors

New IL-17 modulators discovered at UCB

Agios Pharmaceuticals, University of Michigan present menin/MLL interaction inhibitors

Camp Therapeutics identifies new antibacterial peptides

Bayer describes new anthelmintic compounds

New PKP2-based gene therapy for ARVC treatment

Novel AChE/GSK-3beta inhibitor shows promising activity in models of AD

IACTA Pharmaceuticals receives funding to conduct preclinical studies of IC-800

IL-2 partial agonist allows T-cell expansion without differentiation

Researchers develop a novel rotenone-induced murine model of bipolar disorder

Gene therapy provides pain relief by resetting "corrupted" circuit

New AAV/CRISPR strategy corrects complex genetic defects in a severe hemophilia B model

Single-cell atlas of SCLC tumors identifies plasticity, metastasis, and immunosuppression signatures

Dual-targeting CAR-T cell strategy provides sustained antitumor activity and prevents tumor escape

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...